Researchers from the University of Alberta have developed a promising human-derived antimicrobial peptide that could offer a new way to treat infections caused by drug-resistant bacteria and fungi. The discovery represents an important step in the global search for alternatives to conventional antibiotics as antimicrobial resistance (AMR) continues to threaten public health worldwide.

The newly developed peptide, known as D-GK17, is a synthetic version of a naturally occurring human antimicrobial peptide. In preclinical studies, the molecule demonstrated the ability to attack bacterial and fungal cells by disrupting their protective outer membranes and breaking down biofilms—the sticky microbial communities that often shield pathogens from antibiotics and contribute to persistent infections.

Unlike many conventional antibiotics, D-GK17 was designed to remain stable in the body while showing low toxicity to human cells. Researchers believe its mechanism of directly targeting microbial cell membranes makes it significantly more difficult for bacteria to develop resistance, addressing one of the greatest challenges in modern infectious disease treatment.

The research team evaluated the peptide against a range of clinically important bacterial and fungal pathogens, including microorganisms commonly associated with difficult-to-treat infections. Laboratory results indicated strong antimicrobial activity even against organisms protected by biofilms, highlighting its potential for managing chronic and healthcare-associated infections.

Although the findings are encouraging, the researchers emphasize that D-GK17 is still in the preclinical stage. Further studies, including animal and human clinical trials, will be required to establish its safety, effectiveness, optimal dosing, and suitability for clinical use before it can become an approved therapeutic option.

The World Health Organization recognizes antimicrobial resistance as one of the most pressing global health threats. As existing antibiotics become less effective, there is an urgent need for innovative therapies that can overcome resistant pathogens without accelerating the emergence of new resistance mechanisms. Human-derived antimicrobial peptides such as D-GK17 represent one of the promising next-generation strategies being explored to strengthen the global antimicrobial pipeline.

For countries in Africa, where the burden of antimicrobial resistance continues to rise, innovations in peptide-based therapeutics could complement antimicrobial stewardship, infection prevention and control, and One Health approaches aimed at preserving the effectiveness of existing antibiotics.

Reference

University of Alberta researchers. Peptide alternative to antibiotics could combat antimicrobial resistance crisis. Published in Cell Biomaterials and reported by Phys.org.